首页 > 市场调查报告书 > 医疗设备

妇科治疗

全球子宫肌瘤治疗药物市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

市场调查报告书

商品编码

1377903

全球子宫肌瘤治疗药物市场研究报告 - 2023 年至 2030 年产业分析、规模、份额、成长、趋势与预测

Global Uterine Fibroid Treatment Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 172 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录图表

全球子宫肌瘤治疗药物市场需求预计将从 2022 年的 22.9 亿美元增至 2030 年的近 56.3 亿美元，2023-2030 年研究期间CAGR为 11.9%。

子宫肌瘤治疗药物是用来控制子宫肌瘤症状的药物，子宫肌瘤是子宫壁上生长的生长物或肿瘤（非癌性）。这些药物通常在不需要立即进行手术或首选侵入性较小的方法时使用。这些药物可能会导致月经大量出血、骨盆腔疼痛和压力，这些药物的目的是缓解这些症状。

市场动态：

子宫肌瘤治疗药物市场由反映子宫肌瘤的盛行率及其对女性健康影响的多个因素所推动。子宫肌瘤是一种常见的妇科疾病，导致对治疗相关症状的药物的持续需求。月经大量出血、骨盆腔疼痛和压力是促使患者寻求药物介入以提高生活品质的常见症状。许多女性喜欢非手术治疗方案，以避免与手术相关的潜在风险和恢復。子宫肌瘤治疗药物提供了一种侵入性较小的替代方案。此外，一些患有肌瘤的女性希望保留生育能力，因此保留子宫的药物成为一个有吸引力的选择。药物开发的不断进步和患者意识的提高有助于扩大可用治疗选择的范围。临床指引和尽量减少失血（肌瘤的常见症状）的愿望进一步支持这些药物的使用。子宫肌瘤治疗药物也在个人化医疗中发挥作用，可以根据患者的个别需求制定量身定制的治疗计划。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球子宫肌瘤治疗药物市场的各个细分市场进行了包容性评估。子宫肌瘤治疗药物产业的成长和趋势为本研究提供了整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲子宫肌瘤治疗药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。子宫肌瘤治疗药物市场的主要参与者包括Myovant Sciences GmbH、辉瑞公司、艾伯维公司、Ferring BV、阿斯特捷利康、拜耳公司、Amring Pharmaceuticals Inc.、沃森製药公司。本节包括竞争格局的整体视图其中包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

区域展望
介绍
北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析

第 9 章：子宫肌瘤治疗药物公司的竞争格局

子宫肌瘤治疗药物市场竞争
伙伴关係/协作/协议
併购
新产品发布
其他发展

第 10 章：公司简介

公司股份分析
市场集中度
Myovant Sciences GmbH

公司简介
公司收入
产品
最近的发展

Pfizer Inc.

公司简介
公司收入
产品
最近的发展

Abbvie Inc.

公司简介
公司收入
产品
最近的发展

Ferring BV

公司简介
公司收入
产品
最近的发展

AstraZeneca

公司简介
公司收入
产品
最近的发展

Bayer AG

公司简介
公司收入
产品
最近的发展

Amring Pharmaceuticals Inc.

公司简介
公司收入
产品
最近的发展

Watson Pharma Inc.

公司简介
公司收入
产品
最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

简介目录图表

Product Code: VMR112112210

The global demand for Uterine Fibroid Treatment Drugs Market is presumed to reach the market size of nearly USD 5.63 BN by 2030 from USD 2.29 BN in 2022 with a CAGR of 11.9% under the study period 2023 - 2030.

Uterine fibroid treatment drugs are medications prescribed to manage the symptoms of uterine fibroids, which are growths or tumors (non-cancerous) that develop in the wall of the uterus. These drugs are typically used when surgery is not immediately necessary or when a less invasive approach is preferred. These can cause heavy menstrual bleeding, pelvic pain, and pressure, and the goal of these medications is to alleviate these symptoms.

MARKET DYNAMICS:

The Uterine fibroid treatment drugs market is driven by several factors reflecting the prevalence and impact of uterine fibroids on women's health. Uterine fibroids are a common gynecological condition, leading to a consistent demand for medications to manage associated symptoms. Heavy menstrual bleeding, pelvic pain, and pressure are common symptoms that drive patients to seek pharmaceutical interventions enhancing their quality of life. Non-surgical treatment options are preferred by many women to avoid the potential risks and recovery associated with surgery. Uterine fibroid treatment drugs offer a less invasive alternative. Additionally, some women with fibroids aim to preserve fertility, making uterine-sparing medications an appealing choice. Ongoing advancements in drug development and increasing patient awareness contribute to the expanding range of available treatment options. Clinical guidelines and the desire to minimize blood loss, a common symptom of fibroids, further support the use of these medications. Uterine fibroid treatment drugs also play a role in personalized medicine, allowing tailored treatment plans to address individual patient needs.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of uterine fibroid treatment drugs. The growth and trends of uterine fibroid treatment drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the uterine fibroid treatment drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

Gonadotropin-Releasing Hormone (GnRH) Agonists
Gonadotropin-Releasing Hormone (GnRH) Antagonists
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives
Non-Hormonal Medications
Others

By Type

Subserosal Fibroids
Intramural Fibroids
Submucosal Fibroids
Pedunculated Fibroids

By End-User

Hospital Pharmacies
Retail Pharmacies
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Uterine Fibroid Treatment Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Uterine Fibroid Treatment Drugs market include Myovant Sciences GmbH, Pfizer Inc., Abbvie Inc, Ferring B.V., AstraZeneca, Bayer AG, Amring Pharmaceuticals Inc., Watson Pharma Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . UTERINE FIBROID TREATMENT DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Type
- 3.7.3 Market Attractiveness Analysis By End-User
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY DRUG CLASS

5.1 Overview by Drug Class
5.2 Historical and Forecast Data
5.3 Analysis by Drug Class
5.4 Gonadotropin-Releasing Hormone (GnRH) Agonists Historic and Forecast Sales by Regions
5.5 Gonadotropin-Releasing Hormone (GnRH) Antagonists Historic and Forecast Sales by Regions
5.6 Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Historic and Forecast Sales by Regions
5.7 Non-Hormonal Medications Historic and Forecast Sales by Regions
5.8 Others Historic and Forecast Sales by Regions

6 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY TYPE

6.1 Overview by Type
6.2 Historical and Forecast Data
6.3 Analysis by Type
6.4 Subserosal Fibroids Historic and Forecast Sales by Regions
6.5 Intramural Fibroids Historic and Forecast Sales by Regions
6.6 Submucosal Fibroids Historic and Forecast Sales by Regions
6.7 Pedunculated Fibroids Historic and Forecast Sales by Regions

7 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY END-USER

7.1 Overview by End-User
7.2 Historical and Forecast Data
7.3 Analysis by End-User
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Others Historic and Forecast Sales by Regions

8 . GLOBAL UTERINE FIBROID TREATMENT DRUGS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE UTERINE FIBROID TREATMENT DRUGS COMPANIES

9.1. Uterine Fibroid Treatment Drugs Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF UTERINE FIBROID TREATMENT DRUGS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Myovant Sciences GmbH
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. Pfizer Inc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Abbvie Inc.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Ferring B.V.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. AstraZeneca
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Bayer AG
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. Amring Pharmaceuticals Inc.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. Watson Pharma Inc.
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

简介目录图表

LIST OF TABLES

Market Snapshot
Drivers : Impact Analysis
Restraints : Impact Analysis
List of Raw Material
List of Raw Material Manufactures
List of Potential Buyers
Analysis by Drug Class (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
Non-Hormonal Medications Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Analysis Market by Type (USD MN)
Subserosal Fibroids Market Sales by Geography (USD MN)
Intramural Fibroids Market Sales by Geography (USD MN)
Submucosal Fibroids Market Sales by Geography (USD MN)
Pedunculated Fibroids Market Sales by Geography (USD MN)
Analysis by End-User (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Uterine Fibroid Treatment Drugs Market Sales by Geography (USD MN)
North America Market Analysis (USD MN)
United State Market Analysis (USD MN)
Canada Market Analysis (USD MN)
Mexico Market Analysis (USD MN)
Europe Market Analysis (USD MN)
Europe Market Estimate by Country (USD MN)
United Kingdom Market Analysis (USD MN)
France Market Analysis (USD MN)
Germany Market Analysis (USD MN)
Italy Market Analysis (USD MN)
Russia Market Analysis (USD MN)
Spain Market Analysis (USD MN)
Rest of Europe Market Analysis (USD MN)
Asia Pacific Market Analysis (USD MN)
China Market Analysis (USD MN)
Japan Market Analysis (USD MN)
India Market Analysis (USD MN)
South Korea Market Analysis (USD MN)
Australia Market Analysis (USD MN)
South East Asia Market Analysis (USD MN)
Rest of Asia Pacific Market Analysis (USD MN)
Latin America Market Analysis (USD MN)
Brazil Market Analysis (USD MN)
Argentina Market Analysis (USD MN)
Peru Market Analysis (USD MN)
Chile Market Analysis (USD MN)
Rest of Latin America Market Analysis (USD MN)
Middle East & Africa Market Analysis (USD MN)
Saudi Arabia Market Analysis (USD MN)
UAE Market Analysis (USD MN)
Israel Market Analysis (USD MN)
South Africa Market Analysis (USD MN)
Rest of Middle East and Africa Market Analysis (USD MN)
Partnership/Collaboration/Agreement
Mergers And Acquisition

LIST OF FIGURES

Research Scope of Uterine Fibroid Treatment Drugs Report
Market Research Process
Market Research Methodology
Global Uterine Fibroid Treatment Drugs Market Size, by Region (USD MN)
Porters Five Forces Analysis
Market Attractiveness Analysis by Drug Class
Market Attractiveness Analysis by Type
Market Attractiveness Analysis by End-User
Market Attractiveness Analysis by Region
Value Chain Analysis
Global Market Analysis by Drug Class (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Agonists Market Sales by Geography (USD MN)
Gonadotropin-Releasing Hormone (GnRH) Antagonists Market Sales by Geography (USD MN)
Progestin-Releasing Intrauterine Device (IUD) & Contraceptives Market Sales by Geography (USD MN)
Non-Hormonal Medications Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Analysis by Type (USD MN)
Subserosal Fibroids Market Sales by Geography (USD MN)
Intramural Fibroids Market Sales by Geography (USD MN)
Submucosal Fibroids Market Sales by Geography (USD MN)
Pedunculated Fibroids Market Sales by Geography (USD MN)
Global Market Analysis by End-User (USD MN)
Hospital Pharmacies Market Sales by Geography (USD MN)
Retail Pharmacies Market Sales by Geography (USD MN)
Others Market Sales by Geography (USD MN)
Global Market Sales (USD MN)
North America Market Sales (USD MN)
Europe Market Sales (USD MN)
Asia Pacific Market Sales (USD MN)
Latin America Market Sales (USD MN)
Middle East & Africa Market Sales (USD MN)
Recent Development in Industry
Top Company Market Share Analysis